Perspective: Issues with Proposed Regulatory Pathways for Follow-on Biologics

Posted 01 August 2011 | By Alok Byopadhyay, PhD, RAC 

Most small molecule drugs are produced through some chemical synthesis steps and purified through a rigorous process. This enables production of substantially pure active pharmaceutical ingredient (API), which is characterized further by various physical and chemical methods.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.


Most Viewed Articles